Healthcare
Live Price
Offline$0.1865
+0.00% today
1Y Change
+86.50%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) is a Healthcare stock with a market cap of $10.01B and listed on OTC. The stock last traded around $0.19 and up 86.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +34.2%, EPS growth of +180.8%, a dividend yield of 0.9%. What stands out right now is revenue +34.2%, EPS +180.8%, free cash flow -479.2% with operating margin 19.0% and ROIC 2.7%. The dividend is present but secondary, with a yield around 0.9%. Valuation already assumes a fairly strong business story at P/E 58.2 and price/sales 3.9. Stock Foundry combines SHPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHPHF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHPHF Max Drawdown
-23.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHPHF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.5B
-18.9% YoY
FY Net Income
$473.4M
+13.7% YoY
Free Cash Flow
-$279.5M
-534.9% YoY
Revenue Growth
+34.2%
EPS Growth
+180.8%
Gross Margin
68.8%
Net Margin
6.9%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.9B | 2.2B | 3.0B | 2.5B |
| Gross Profit | 1.2B | 1.3B | 1.5B | 2.4B | 1.9B |
| Operating Income | -138M | 162M | -1.8B | 772M | 787M |
| EBITDA | 105M | 334M | -1.5B | 932M | 714M |
| Net Income | -217M | -54M | -1.9B | 417M | 473M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.6B | 3.9B | 3.8B | 5.7B | 4.6B |
| Total Assets | 10.5B | 11.5B | 12.1B | 14.5B | 13.0B |
| Total Liabilities | 5.6B | 6.4B | 6.5B | 5.3B | 3.1B |
| Shareholder Equity | 4.4B | 4.4B | 4.7B | 8.3B | 9.2B |
| Total Debt | 974M | 1.3B | 1.3B | 1.1B | 755M |
| Net Debt | -2.6B | -2.6B | -2.6B | -4.6B | -3.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
227M
-65.9% YoY
Capital Expenditures
507M
+15.7% YoY
Free Cash Flow
280M
-534.9% YoY
Key ratios
Gross Margin
68.8%
Operating Margin
19.0%
Net Margin
6.9%
ROE
3.5%
Debt / Equity
0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.